ARRC – Autoimmune Resource & Research Centre

GRIPHON OL study is now closed at this site.

The GRIPHON study researched Selexipag, a drug which has now been approved for use in Australia to treat Pulmonary Arterial Hypertension (PAH). This was an International Clinical Trial by Actelion Pharmaceuticals.